Early metabolic markers that anticipate loss of insulin independence in type 1 diabetic islet allograft recipients

D. Hirsch, J. Odorico, J. S. Danobeitia, Rodolfo Alejandro, M. R. Rickels, M. Hanson, N. Radke, David Baidal, D. Hullett, A. Naji, Camillo Ricordi, D. Kaufman, L. Fernandez

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The objective of this study was to identify predictors of insulin independence and to establish the best clinical tools to follow patients after pancreatic islet transplantation (PIT). Sequential metabolic responses to intravenous (I.V.) glucose (I.V. glucose tolerance test [IVGTT]), arginine and glucose-potentiated arginine (glucose-potentiated arginine-induced insulin secretion [GPAIS]) were obtained from 30 patients. We determined the correlation between transplanted islet mass and islet engraftment and tested the ability of each assay to predict return to exogenous insulin therapy. We found transplanted islet mass within an average of 16 709 islet equivalents per kg body weight (IEQ/kg BW; range between 6602 and 29 614 IEQ/kg BW) to be a poor predictor of insulin independence at 1 year, having a poor correlation between transplanted islet mass and islet engraftment. Acute insulin response to IVGTT (AIR GLU) and GPAIS (AIR max) were the most accurate methods to determine suboptimal islet mass engraftment. AIR GLU performed 3 months after transplant also proved to be a robust early metabolic marker to predict return to insulin therapy and its value was positively correlated with duration of insulin independence. In conclusion, AIR GLU is an early metabolic assay capable of anticipating loss of insulin independence at 1 year in T1D patients undergoing PIT and constitutes a valuable, simple and reliable method to follow patients after transplant. Acute insulin response to an intravenous glucose tolerance test is the most reliable predictor of insulin independence at one year after pancreatic islet transplantation in type 1 diabetic recipients.

Original languageEnglish
Pages (from-to)1275-1289
Number of pages15
JournalAmerican Journal of Transplantation
Volume12
Issue number5
DOIs
StatePublished - May 1 2012

Fingerprint

Allografts
Insulin
Islets of Langerhans Transplantation
Arginine
Glucose Tolerance Test
Glucose
Transplants
Body Weight
Therapeutics

Keywords

  • Clinical islet transplantation
  • insulin independence

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Early metabolic markers that anticipate loss of insulin independence in type 1 diabetic islet allograft recipients. / Hirsch, D.; Odorico, J.; Danobeitia, J. S.; Alejandro, Rodolfo; Rickels, M. R.; Hanson, M.; Radke, N.; Baidal, David; Hullett, D.; Naji, A.; Ricordi, Camillo; Kaufman, D.; Fernandez, L.

In: American Journal of Transplantation, Vol. 12, No. 5, 01.05.2012, p. 1275-1289.

Research output: Contribution to journalArticle

Hirsch, D, Odorico, J, Danobeitia, JS, Alejandro, R, Rickels, MR, Hanson, M, Radke, N, Baidal, D, Hullett, D, Naji, A, Ricordi, C, Kaufman, D & Fernandez, L 2012, 'Early metabolic markers that anticipate loss of insulin independence in type 1 diabetic islet allograft recipients', American Journal of Transplantation, vol. 12, no. 5, pp. 1275-1289. https://doi.org/10.1111/j.1600-6143.2011.03947.x
Hirsch, D. ; Odorico, J. ; Danobeitia, J. S. ; Alejandro, Rodolfo ; Rickels, M. R. ; Hanson, M. ; Radke, N. ; Baidal, David ; Hullett, D. ; Naji, A. ; Ricordi, Camillo ; Kaufman, D. ; Fernandez, L. / Early metabolic markers that anticipate loss of insulin independence in type 1 diabetic islet allograft recipients. In: American Journal of Transplantation. 2012 ; Vol. 12, No. 5. pp. 1275-1289.
@article{f6ed5609e7d0438db884baddf528d514,
title = "Early metabolic markers that anticipate loss of insulin independence in type 1 diabetic islet allograft recipients",
abstract = "The objective of this study was to identify predictors of insulin independence and to establish the best clinical tools to follow patients after pancreatic islet transplantation (PIT). Sequential metabolic responses to intravenous (I.V.) glucose (I.V. glucose tolerance test [IVGTT]), arginine and glucose-potentiated arginine (glucose-potentiated arginine-induced insulin secretion [GPAIS]) were obtained from 30 patients. We determined the correlation between transplanted islet mass and islet engraftment and tested the ability of each assay to predict return to exogenous insulin therapy. We found transplanted islet mass within an average of 16 709 islet equivalents per kg body weight (IEQ/kg BW; range between 6602 and 29 614 IEQ/kg BW) to be a poor predictor of insulin independence at 1 year, having a poor correlation between transplanted islet mass and islet engraftment. Acute insulin response to IVGTT (AIR GLU) and GPAIS (AIR max) were the most accurate methods to determine suboptimal islet mass engraftment. AIR GLU performed 3 months after transplant also proved to be a robust early metabolic marker to predict return to insulin therapy and its value was positively correlated with duration of insulin independence. In conclusion, AIR GLU is an early metabolic assay capable of anticipating loss of insulin independence at 1 year in T1D patients undergoing PIT and constitutes a valuable, simple and reliable method to follow patients after transplant. Acute insulin response to an intravenous glucose tolerance test is the most reliable predictor of insulin independence at one year after pancreatic islet transplantation in type 1 diabetic recipients.",
keywords = "Clinical islet transplantation, insulin independence",
author = "D. Hirsch and J. Odorico and Danobeitia, {J. S.} and Rodolfo Alejandro and Rickels, {M. R.} and M. Hanson and N. Radke and David Baidal and D. Hullett and A. Naji and Camillo Ricordi and D. Kaufman and L. Fernandez",
year = "2012",
month = "5",
day = "1",
doi = "10.1111/j.1600-6143.2011.03947.x",
language = "English",
volume = "12",
pages = "1275--1289",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Early metabolic markers that anticipate loss of insulin independence in type 1 diabetic islet allograft recipients

AU - Hirsch, D.

AU - Odorico, J.

AU - Danobeitia, J. S.

AU - Alejandro, Rodolfo

AU - Rickels, M. R.

AU - Hanson, M.

AU - Radke, N.

AU - Baidal, David

AU - Hullett, D.

AU - Naji, A.

AU - Ricordi, Camillo

AU - Kaufman, D.

AU - Fernandez, L.

PY - 2012/5/1

Y1 - 2012/5/1

N2 - The objective of this study was to identify predictors of insulin independence and to establish the best clinical tools to follow patients after pancreatic islet transplantation (PIT). Sequential metabolic responses to intravenous (I.V.) glucose (I.V. glucose tolerance test [IVGTT]), arginine and glucose-potentiated arginine (glucose-potentiated arginine-induced insulin secretion [GPAIS]) were obtained from 30 patients. We determined the correlation between transplanted islet mass and islet engraftment and tested the ability of each assay to predict return to exogenous insulin therapy. We found transplanted islet mass within an average of 16 709 islet equivalents per kg body weight (IEQ/kg BW; range between 6602 and 29 614 IEQ/kg BW) to be a poor predictor of insulin independence at 1 year, having a poor correlation between transplanted islet mass and islet engraftment. Acute insulin response to IVGTT (AIR GLU) and GPAIS (AIR max) were the most accurate methods to determine suboptimal islet mass engraftment. AIR GLU performed 3 months after transplant also proved to be a robust early metabolic marker to predict return to insulin therapy and its value was positively correlated with duration of insulin independence. In conclusion, AIR GLU is an early metabolic assay capable of anticipating loss of insulin independence at 1 year in T1D patients undergoing PIT and constitutes a valuable, simple and reliable method to follow patients after transplant. Acute insulin response to an intravenous glucose tolerance test is the most reliable predictor of insulin independence at one year after pancreatic islet transplantation in type 1 diabetic recipients.

AB - The objective of this study was to identify predictors of insulin independence and to establish the best clinical tools to follow patients after pancreatic islet transplantation (PIT). Sequential metabolic responses to intravenous (I.V.) glucose (I.V. glucose tolerance test [IVGTT]), arginine and glucose-potentiated arginine (glucose-potentiated arginine-induced insulin secretion [GPAIS]) were obtained from 30 patients. We determined the correlation between transplanted islet mass and islet engraftment and tested the ability of each assay to predict return to exogenous insulin therapy. We found transplanted islet mass within an average of 16 709 islet equivalents per kg body weight (IEQ/kg BW; range between 6602 and 29 614 IEQ/kg BW) to be a poor predictor of insulin independence at 1 year, having a poor correlation between transplanted islet mass and islet engraftment. Acute insulin response to IVGTT (AIR GLU) and GPAIS (AIR max) were the most accurate methods to determine suboptimal islet mass engraftment. AIR GLU performed 3 months after transplant also proved to be a robust early metabolic marker to predict return to insulin therapy and its value was positively correlated with duration of insulin independence. In conclusion, AIR GLU is an early metabolic assay capable of anticipating loss of insulin independence at 1 year in T1D patients undergoing PIT and constitutes a valuable, simple and reliable method to follow patients after transplant. Acute insulin response to an intravenous glucose tolerance test is the most reliable predictor of insulin independence at one year after pancreatic islet transplantation in type 1 diabetic recipients.

KW - Clinical islet transplantation

KW - insulin independence

UR - http://www.scopus.com/inward/record.url?scp=84860432769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860432769&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2011.03947.x

DO - 10.1111/j.1600-6143.2011.03947.x

M3 - Article

VL - 12

SP - 1275

EP - 1289

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 5

ER -